Geron Corp
GERNGeron Corporation is a biotechnology company focusing on developing innovative therapies for cancer and regenerative medicine. It is known for its work in telomerase inhibition, aiming to treat cancer by targeting the enzyme crucial for cancer cell immortality, and exploring strategies for tissue repair and regenerative therapies.
Company News
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
Law firm investigating potential claims against Geron Corporation regarding alleged misleading statements about drug Rytelo's launch and growth potential during February 2024-2025 period.
Geron, a commercial-stage biotech company, reported its Q1 2023 results, which fell short of analyst expectations. While the company's cancer drug Rytelo generated $39.6 million in sales, it was lower than the $50.5 million analysts had projected. Geron maintained its guidance for operating expenses and cash runway.
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
All three small-cap biotech/biopharma stocks have attractive risk/reward profiles and potential catalysts on the horizon. Click here for the complete stock list.
